Mylan N.V. and Biocon Ltd. announced that the FDA has approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim), co-developed...
Mylan notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a...
Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has...
Mylan and Biocon, announced on 28 April 2020 the launch of their pegfilgrastim biosimilar, Fulphila, in Canada. This is the second biosimilar from the pair to be launched in the country.
Spectrum Pharmaceuticals announced that the company submitted a Biologics License Application (BLA) with the FDA for Rolontis (eflapegrastim) for chemotherapy-induced...
Sandoz, a Novartis division and a global leader in biosimilars, announced that the FDA approved its biosimilar Ziextenzo (pegfilgrastim-bmez). Sandoz...
Spectrum Pharmaceuticals, Inc. has announced detailed data from the ADVANCE Phase III study which showed that Rolontis had an absolute...